# HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant

> **NCT02902120** · PHASE4 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 21 (actual)

## Conditions studied

- Hepatitis C
- Renal Insufficiency, Chronic
- Disorder of Transplanted Kidney

## Interventions

- **DRUG:** Post-transplant Grazoprevir and Elbasvir

## Key facts

- **NCT ID:** NCT02902120
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-01
- **Primary completion:** 2021-09-01
- **Final completion:** 2022-06-08
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02902120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02902120, "HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02902120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*